<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>üíä Lessons for Modern Drug Development from the Golden Age of Antibiotics - Just-in-Time Learning</title>
  <link rel="stylesheet" href="/style.css">
</head>
<body>
  <header>
    <div class="container">
      <h1>Just-in-Time Learning</h1>
      <p class="subtitle">Inquisitive. Learning. Sharing. Simplicity = Reliability</p>
      <nav>
        <a href="/" class="back-link">‚Üê Back to Home</a>
      </nav>
    </div>
  </header>

  <main class="post-container">
    <article class="post">
      <header class="post-header">
        <h1>üíä Lessons for Modern Drug Development from the Golden Age of Antibiotics</h1>
        <span class="post-date">January 7, 2025</span>
        <div class="post-tags">
          <span class="post-tag">iterative-refinement</span><span class="post-tag">evolution</span><span class="post-tag">data-science</span><span class="post-tag">evaluation</span><span class="post-tag">decision-making</span><span class="post-tag">best-practices</span><span class="post-tag">modelling-mindsets</span><span class="post-tag">production</span>
        </div>
      </header>
      
      <div class="post-content">
        <p>
<strong>TL;DR:</strong> Despite our vastly superior modern technology, antibiotic development has dramatically declined since the post-WWII ‚ÄúGolden Age‚Äù (1940s-1960s) that produced most antibiotic classes we still use today-highlighting how scientific capability alone cannot drive progress without three key elements working together: economic incentives that correct market failures, institutional coordination, and systematic application of technological tools.</p>
<!--more-->
<h2>
Introduction</h2>
<p>
In a thought-provoking analysis[^1], Our World in Data reveals a striking paradox in medical progress: the most productive period in antibiotic development occurred in the two decades following World War II, with scientific capabilities far more limited than today. This ‚ÄúGolden Age of Antibiotics‚Äù (1940s-1960s) produced nearly two-thirds of the antibiotic drug classes we still rely on[^2].\ Even more surprisingly, since 1970 -despite exponential advances in computing power and biotechnology- only eight new classes of antibiotics have been approved[^2]. This indicates a stark decline that threatens the foundation of modern medicine. Traditional screening methods now rediscover existing compounds most of the time rather than finding new ones[^3].\ Modern tools like genome sequencing and systematic screening methods offer unprecedented capabilities. We‚Äôve only identified a small fraction of bacterial species, many of which could harbour new antibiotic compounds[^2]. Yet despite these capabilities, development has stagnated due to fundamental market failures and fragmented research efforts.\ This article examines this paradoxical inverse relationship between technological capability and antibiotic development: How did the Golden Age achieve such remarkable success with limited tools? Why has progress slowed as our capabilities have grown? Most importantly, what combinations of economic incentives and modern technology could spark a new era of antibiotic discovery?</p>
<h2>
When Urgency Met Innovation</h2>
<p>
The Golden Age of Antibiotics stands as medicine‚Äôs most productive period in antimicrobial discovery, yielding over 20 new antibiotic classes -more than double what we‚Äôve developed in the 50 years since[^2]. Three pivotal breakthroughs, coupled with unprecedented coordination, drove this remarkable success.\ The foundation was laid by Paul Ehrlich‚Äôs systematic approach to drug discovery. By methodically testing hundreds of compounds, he discovered <a href="https://en.wikipedia.org/wiki/Arsphenamine">salvarsan</a> in 1910 -the first synthetic antibiotic that effectively treated syphilis[^2]. A second milestone emerged when Alexander Fleming discovered penicillin in 1928. However, the real innovation came through coordinated wartime effort. With infections being the second-most common cause of hospital admissions in the US Army, the U.S. Office of Scientific Research and Development (OSRD) launched a global search for more productive penicillin strains, ultimately finding a high-yielding strain on a cantaloupe[^4].\ The third breakthrough came from Selman Waksman‚Äôs insight into soil bacteria. His discovery that soil-dwelling <a href="https://en.wikipedia.org/wiki/Actinomycetales">actinomycetes</a> bacteria naturally produce antibiotics led to <a href="https://en.wikipedia.org/wiki/Streptomycin">streptomycin</a>‚Äòs development and opened an entirely new avenue for antibiotic discovery[^5].\ What transformed these breakthroughs into a ‚Äúgolden age‚Äù was unprecedented coordination. The U.S. War Production Board orchestrated collaboration between government, academia, and industry -removing patent restrictions, sharing data, and streamlining clinical trials[^6]. The results were remarkable: some antibiotics, like <a href="https://en.wikipedia.org/wiki/Tetracycline_antibiotics">tetracyclines</a> and <a href="https://en.wikipedia.org/wiki/Macrolide">macrolides</a>, went from discovery to clinical use within the same year.</p>
<h2>
Scientific Progress and Market Failure</h2>
<p>
The contrast between the Golden Age and our current era reflects a fundamental misalignment between public health needs and market incentives[^2]. The market structure fundamentally disfavours antibiotics in two ways:</p>
<ol>
  <li>
Revenue Structure: While chronic disease medications can generate billions in  </li>
  <li>
Conservation Requirements: New antibiotics must be reserved for severe    <br>
annual revenue over decades, new antibiotics typically generate only tens of    millions annually[^7], by comparison. This revenue gap has driven many large    pharmaceutical companies away from antibiotic development[^8].    drug-resistant infections, reaching less than 1% of hospitalised    patients[^7]. This necessary conservation practice severely limits market    potential.  </li>
</ol>
<p>
Meanwhile, our technological capabilities offer three particularly promising approaches:</p>
<ol>
  <li>
Genome mining: a breakthrough technique that identifies hidden antibiotic  </li>
  <li>
Advanced bacterial exploration: research into extreme environments like deep  </li>
  <li>
Smart combination strategies: exploiting the observation that bacterial    <br>
genes in microbes that remain dormant under standard laboratory conditions.    This computational approach has already yielded promising candidates like    humimycins[^9].    oceans and deserts, where previously ‚Äúunculturable‚Äù bacteria might harbour    entirely new antibiotic classes[^3].    resistance to one antibiotic can increase vulnerability to others, opening    new therapeutic possibilities[^10].  </li>
</ol>
<p>
Yet these powerful tools remain underutilised due to insufficient investment and coordination. The challenge isn‚Äôt scientific capability -it‚Äôs the failure to create systems that effectively deploy these technologies within sustainable economic frameworks.</p>
<h2>
Integrating Economics and Technology</h2>
<p>
Drawing from evidence in antibiotic development research, several promising approaches could help overcome current market failures while leveraging modern technological capabilities[^7].</p>
<h3>
Economic Solutions to Market Failures</h3>
<ol>
  <li>
Subscription Models: The UK has pioneered a system where healthcare systems  </li>
  <li>
Advance Market Commitments: These provide guaranteed payments to companies  </li>
  <li>
Collaborative Funding Initiatives: Organisations like CARB-X and GARDP help    <br>
pay annual fees for antibiotic access rather than per-volume pricing. This    addresses both the revenue challenge and conservation requirements by    providing stable income while supporting appropriate antibiotic use[^7].    that successfully develop new antibiotics, similar to successful vaccine    development programs. This directly addresses the revenue uncertainty that    has driven companies away from antibiotic development[^11].    smaller companies navigate costly clinical trials, distributing development    risks that large pharmaceutical companies are unwilling to bear[^7].  </li>
</ol>
<h3>
Leveraging Modern Technology</h3>
<p>
To maximise the impact of these economic incentives, three technological approaches show particular promise:</p>
<ol>
  <li>
Systematic Genome Mining: Using computational power to identify promising  </li>
  <li>
Environmental Exploration: Research into extreme environments could unlock  </li>
  <li>
Smart Combination Strategies: Systematic exploration of how resistance to one    <br>
antibiotic-producing genes in bacterial genomes, revealing compounds that    traditional screening would miss[^9].    entirely new antibiotic classes, enabled by modern sequencing    technologies[^3].    antibiotic can increase vulnerability to others, offering new therapeutic    possibilities[^10].  </li>
</ol>
<h2>
Conclusion</h2>
<p>
The story of antibiotic development demonstrates that scientific capability alone cannot drive progress. The Golden Age succeeded through a powerful combination of systematic approaches, unprecedented collaboration, and removal of institutional barriers -even with limited technological tools[^2].\ Today‚Äôs challenge is fundamentally different. We possess sophisticated tools -from genome mining to advanced screening methods- yet development has stalled. This paradox reveals that progress requires three key elements working in concert: economic incentives, institutional coordination, and technological application[^7].\ The evidence-based solutions presented in the original Our World in Data article[^1] offer a path forward. Market reforms like subscription models and advance market commitments could help correct the fundamental economic misalignment in antibiotic development[^8]. Meanwhile, systematic application of computational tools, genomic analysis, and bacterial exploration could help unlock new classes of antibiotics that traditional methods miss[^9].\ The urgency is clear. Antimicrobial resistance threatens to undermine many advances in modern medicine[^12]. However, by combining proven coordination approaches from the Golden Age with modern capabilities and sustainable economic frameworks, we can revitalise antibiotic development for the challenges ahead.</p>
<hr class="thin">
<p>
[^1]: Our World in Data (2024). ‚ÄúWhat was the Golden Age of Antibiotics, and how</p>
<pre><code>can we spark a new one?&quot;
[https://ourworldindata.org/golden-age-antibiotics](https://ourworldindata.org/golden-age-antibiotics)</code></pre>
<p>
[^2]: Hutchings, M. I., Truman, A. W., &amp; Wilkinson, B. (2019). Antibiotics:</p>
<pre><code>Past, present and future. Current Opinion in Microbiology, 51, 72‚Äì80.
[https://doi.org/10.1016/j.mib.2019.10.008](https://doi.org/10.1016/j.mib.2019.10.008)</code></pre>
<p>
[^3]: Kolter, R., &amp; Van Wezel, G. P. (2016). Goodbye to brute force in</p>
<pre><code>antibiotic discovery? Nature Microbiology, 1(2), 15020.
[https://doi.org/10.1038/nmicrobiol.2015.20](https://doi.org/10.1038/nmicrobiol.2015.20)</code></pre>
<p>
[^4]: Gaynes, R. (2017). The Discovery of Penicillin -New Insights After More</p>
<pre><code>Than 75 Years of Clinical Use. Emerging Infectious Diseases, 23(5), 849‚Äì853.
[https://doi.org/10.3201/eid2305.161556](https://doi.org/10.3201/eid2305.161556)</code></pre>
<p>
[^5]: Waksman, S. A., &amp; Schatz, A. (1945). Streptomycin‚ÄìOrigin, Nature, and</p>
<pre><code>Properties. Journal of the American Pharmaceutical Association, 34(11),
273‚Äì291.
[https://doi.org/10.1002/jps.3030341102](https://doi.org/10.1002/jps.3030341102)</code></pre>
<p>
[^6]: Sampat, B. N. (2023). Second World War and the Direction of Medical</p>
<pre><code>Innovation. SSRN Electronic Journal.
[https://doi.org/10.2139/ssrn.4422261](https://doi.org/10.2139/ssrn.4422261)</code></pre>
<p>
[^7]: √Ördal, C., et al. (2020). Antibiotic development -economic, regulatory and</p>
<pre><code>societal challenges. Nature Reviews Microbiology, 18(5), 267-274.
[https://doi.org/10.1038/s41579-019-0293-3](https://doi.org/10.1038/s41579-019-0293-3)</code></pre>
<p>
[^8]: Renwick, M. J., Brogan, D. M., &amp; Mossialos, E. (2016). A systematic review</p>
<pre><code>and critical assessment of incentive strategies for discovery and
development of novel antibiotics. The Journal of Antibiotics, 69(2), 73-88.
[https://doi.org/10.1038/ja.2015.98](https://doi.org/10.1038/ja.2015.98)</code></pre>
<p>
[^9]: Chu, J., et al. (2016). Discovery of MRSA active antibiotics using primary</p>
<pre><code>sequence from the human microbiome. Nature Chemical Biology, 12(12),
1004-1006.
[https://doi.org/10.1038/nchembio.2207](https://doi.org/10.1038/nchembio.2207)</code></pre>
<p>
[^10]: Baym, M., Stone, L. K., &amp; Kishony, R. (2016). Multidrug evolutionary</p>
<pre><code>strategies to reverse antibiotic resistance. Science, 351(6268), aad3292.
[https://doi.org/10.1126/science.aad3292](https://doi.org/10.1126/science.aad3292)</code></pre>
<p>
[^11]: Kremer, M., Levin, J., &amp; Snyder, C. M. (2020). Advance Market</p>
<pre><code>Commitments: Insights from Theory and Experience. AEA Papers and
Proceedings, 110, 269-273.
[https://www.aeaweb.org/articles?id=10.1257/pandp.20201017](https://www.aeaweb.org/articles?id=10.1257/pandp.20201017)</code></pre>
<p>
[^12]: World Health Organization (2024). Antimicrobial Resistance Fact Sheet.</p>
<pre><code>[https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance](https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance)</code></pre>

      </div>
    </article>
  </main>

  <footer>
    <div class="container">
      <p>Created with <a href="https://github.com/ai-mindset/init.vim">Neovim</a>, using <a href="https://ai-mindset.github.io/dialogue-engineering">AI</a> to help process and curate content ‚ú®</p>
    </div>
  </footer>

  <script src="/script.js"></script>
</body>
</html>